Jiangsu H鞥R UI medicine co., Ltd.
This study used a single-dose, open and fixed sequence design to compare the pharmacokinetics in healthy subjects.
B-cell Tumors
SHR1459 tablet
Efavirenz tablets
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 20 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | Study of the Pharmacokinetic Effects of Efavirenz on the Pharmacokinetics of SHR1459 in Healthy Subjects |
Actual Study Start Date : | November 4, 2022 |
Estimated Primary Completion Date : | December 2, 2022 |
Estimated Study Completion Date : | January 27, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: healthy subjects |
Drug: SHR1459 tablet Drug: Efavirenz tablets |
Ages Eligible for Study: | 18 Years to 45 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
The First People's Hospital of Lianyungang
Lianyungang, Jiangsu, China, 222002